These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12452297)

  • 21. [How to approach management of an outbreak caused by enterococci].
    Pasquarella C
    Ann Ig; 2000; 12(4 Suppl 2):115-21. PubMed ID: 11100561
    [No Abstract]   [Full Text] [Related]  

  • 22. Prospective vancomycin audit in Auckland healthcare hospitals.
    Drinkovic D; Taylor SL; Pottumarthy S; Morris AJ
    N Z Med J; 1999 Sep; 112(1095):336-9. PubMed ID: 10553935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines for the prevention and control of vancomycin resistant enterococci (VRE) in long-term care facilities. Sioux Falls Task Force on Antimicrobial Resistance.
    S D J Med; 1998 Apr; 51(4):127-32. PubMed ID: 9577692
    [No Abstract]   [Full Text] [Related]  

  • 24. Vancomycin use in a hospital with vancomycin restriction.
    Roghmann MC; Perdue BE; Polish L
    Infect Control Hosp Epidemiol; 1999 Jan; 20(1):60-3. PubMed ID: 9927270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin use in hospitalized pediatric patients.
    Keyserling HL; Sinkowitz-Cochran RL; Harris JM; Levine GL; Siegel JD; Stover BH; Lau SA; Jarvis WR;
    Pediatrics; 2003 Aug; 112(2):e104-11. PubMed ID: 12897315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention.
    Johnson SV; Hoey LL; Vance-Bryan K
    Pharmacotherapy; 1995; 15(5):579-85. PubMed ID: 8570429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy.
    Bond CA; Raehl CL
    Am J Health Syst Pharm; 2005 Aug; 62(15):1596-605. PubMed ID: 16030370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital policy fights resistant bacteria.
    Simmons J
    Qual Lett Healthc Lead; 1998 Jul; 10(7):15. PubMed ID: 10182815
    [No Abstract]   [Full Text] [Related]  

  • 29. Protecting your patients from VRE.
    Burns LA
    Am J Nurs; 1996 Aug; 96(8):23. PubMed ID: 8712235
    [No Abstract]   [Full Text] [Related]  

  • 30. Enemy within. Basic weapons can foil VRE (vancomycin-resistant enterococcus).
    Pugliese G
    Mater Manag Health Care; 1997 Sep; 6(9):32, 34, 36-8. PubMed ID: 10173223
    [No Abstract]   [Full Text] [Related]  

  • 31. Vancomycin-resistant Enterococci. Prevalence and risk factors for fecal carriage in patients at tertiary care hospitals.
    El-Amin NM; Faidah HS
    Saudi Med J; 2011 Sep; 32(9):966-7. PubMed ID: 21894365
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus.
    Edmond M
    Infect Control Hosp Epidemiol; 2003 May; 24(5):309-10; author reply 310-2. PubMed ID: 12785400
    [No Abstract]   [Full Text] [Related]  

  • 33. Measures to Prevent and Control Vancomycin-Resistant Enterococci: Do They Really Matter?
    Humphreys H
    Infect Control Hosp Epidemiol; 2017 Apr; 38(4):507-509. PubMed ID: 28132649
    [No Abstract]   [Full Text] [Related]  

  • 34. A vancomycin monitoring program at a community hospital.
    Goeckner BJ; Hendershot E; Scott K; Drake M
    Jt Comm J Qual Improv; 1998 Jul; 24(7):379-85. PubMed ID: 9689571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infection control can help keep VRE in check.
    Steele T
    Nephrol News Issues; 1999 May; 13(5):37. PubMed ID: 10578822
    [No Abstract]   [Full Text] [Related]  

  • 36. Improving the appropriateness of vancomycin use by sequential interventions.
    Lipsky BA; Baker CA; McDonald LL; Suzuki NT
    Am J Infect Control; 1999 Apr; 27(2):84-91. PubMed ID: 10196484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre.
    Shaikh ZH; Osting CA; Hanna HA; Arbuckle RB; Tarr JJ; Raad II
    J Hosp Infect; 2002 May; 51(1):52-8. PubMed ID: 12009821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A guide to TB, VRE, and MRSA.
    RN; 1998 Jul; 61(7):24DD. PubMed ID: 9687812
    [No Abstract]   [Full Text] [Related]  

  • 39. Action on antibiotics lacking. Most hospitals still aren't managing use: survey.
    DerGurahian J
    Mod Healthc; 2008 Dec 22-29; 38(51):10-1. PubMed ID: 19177671
    [No Abstract]   [Full Text] [Related]  

  • 40. Guidelines for the control of glycopeptide-resistant enterococci in hospitals.
    Cookson BD; Macrae MB; Barrett SP; Brown DF; Chadwick C; French GL; Hateley P; Hosein IK; Wade JJ;
    J Hosp Infect; 2006 Jan; 62(1):6-21. PubMed ID: 16310890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.